IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 320 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,214,068 | +9.6% | 203,132 | -0.9% | 3.61% | +10.7% |
| Q2 2023 | $8,408,975 | +11.7% | 204,947 | -2.7% | 3.27% | +11.5% |
| Q1 2023 | $7,530,347 | -19.0% | 210,698 | -14.4% | 2.93% | -10.7% |
| Q4 2022 | $9,301,165 | -17.2% | 246,258 | -3.0% | 3.28% | -17.7% |
| Q3 2022 | $11,233,000 | +5.1% | 253,976 | -12.0% | 3.98% | +19.7% |
| Q2 2022 | $10,690,000 | -5.3% | 288,751 | -5.3% | 3.33% | +13.9% |
| Q1 2022 | $11,289,000 | +30.8% | 304,782 | +7.9% | 2.92% | +29.7% |
| Q4 2021 | $8,628,000 | -11.7% | 282,531 | -3.0% | 2.25% | -15.4% |
| Q3 2021 | $9,769,000 | -33.5% | 291,254 | -20.9% | 2.66% | -23.9% |
| Q2 2021 | $14,696,000 | -11.7% | 368,409 | -0.5% | 3.50% | -20.5% |
| Q1 2021 | $16,649,000 | -26.9% | 370,298 | -8.1% | 4.40% | -21.7% |
| Q4 2020 | $22,780,000 | +14.8% | 402,908 | -3.7% | 5.62% | -5.1% |
| Q3 2020 | $19,848,000 | -19.7% | 418,295 | -0.3% | 5.93% | -25.1% |
| Q2 2020 | $24,726,000 | +21.7% | 419,372 | -2.4% | 7.91% | +2.2% |
| Q1 2020 | $20,319,000 | -18.1% | 429,752 | +4.6% | 7.74% | -6.4% |
| Q4 2019 | $24,817,000 | +0.9% | 410,812 | +0.1% | 8.27% | +2.4% |
| Q3 2019 | $24,595,000 | -7.4% | 410,537 | -0.7% | 8.07% | -25.2% |
| Q2 2019 | $26,567,000 | -21.5% | 413,372 | -0.9% | 10.80% | -24.5% |
| Q1 2019 | $33,847,000 | +20.0% | 416,985 | -20.1% | 14.30% | +4.7% |
| Q4 2018 | $28,217,000 | +4.4% | 521,959 | -0.4% | 13.66% | +5.4% |
| Q3 2018 | $27,020,000 | +23.8% | 523,844 | -0.0% | 12.96% | +13.2% |
| Q2 2018 | $21,831,000 | +42.8% | 523,894 | +51.1% | 11.45% | +25.4% |
| Q1 2018 | $15,287,000 | -23.7% | 346,812 | -12.9% | 9.13% | -13.6% |
| Q4 2017 | $20,023,000 | +1.5% | 398,072 | +2.3% | 10.57% | -25.1% |
| Q3 2017 | $19,724,000 | +0.1% | 389,022 | +0.4% | 14.11% | -1.5% |
| Q2 2017 | $19,703,000 | +33.4% | 387,322 | +5.4% | 14.32% | +34.2% |
| Q1 2017 | $14,768,000 | +10.2% | 367,360 | +31.1% | 10.67% | +15.3% |
| Q4 2016 | $13,407,000 | – | 280,315 | – | 9.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,046 | $126,557 | 6.89% |
| M28 Capital Management LP | 126,300 | $4,513,962 | 5.10% |
| Bellevue Group AG | 9,511,900 | $339,955,306 | 4.93% |
| Deep Track Capital, LP | 2,834,069 | $101,289,626 | 4.16% |
| BVF INC/IL | 2,560,761 | $91,521,598 | 3.35% |
| Sicart Associates LLC | 210,698 | $7,530,347 | 2.93% |
| Privium Fund Management B.V. | 182,773 | $6,532,307 | 2.19% |
| Camber Capital Management LP | 1,925,000 | $68,800 | 2.12% |
| Orbimed Advisors | 2,124,500 | $75,929,630 | 1.49% |
| SECTOR GAMMA AS | 146,441 | $5,233,801 | 1.27% |